The Limited Times

Now you can see non-English news...

Sanofi will cut into research and development, 400 positions at risk

2021-01-18T08:26:30.512Z


After the announcement in June of a plan to cut 1,700 jobs at Sanofi, nearly 400 jobs are threatened in France in the sector of


The pill has trouble getting through to Sanofi employees.

The pharmaceutical group Sanofi is, according to the unions on France Inter, on the verge of cutting 400 positions in the research and development branch of its pharmaceutical sector.

"The very words of the managing director were categorical: 400 job cuts in pharmaceutical R&D in France, this is not acceptable," denounces Thierry Bodin, CGT-Sanofi delegate, adding that these job cuts are "worrying" while the company is behind in the global race for the Covid-19 vaccine.

"The losses of expertise that we have had in recent years we pay cash", he believes.

READ ALSO>

Covid-19: but what can the Sanofi vaccine still be used for?


Arrived at the helm in September 2019, Paul Hudson, the new boss had warned that he would have to refocus the portfolio, in other words review the priorities at Sanofi.

An "unacceptable" plan

In June, management announced its reorganization plan: 1,700 jobs cut in Europe, including 1,000 in France.

Deletions that would go through departure plans.

According to the unions, concerning the 1,000 positions affected in France, all Sanofi entities are concerned except Vaccines Pasteur (Marcy - Val-de-Reuil) and Genzyme Polyclonal (Lyon).

The profiles of the abolished positions are mainly in support functions and research and development.

Already during the summer, the unions had denounced a plan "unacceptable" by estimating that the company is preparing because of the projects of reorganization to "cut 5,000 jobs in the world over the 2 to 3 years to come".

According to unions, the pharmaceutical group would go with this new starting car from 6,000 positions in research and development in 2007 to less than 3,000 today.

Sanofi is doing well

In reality, the group, for the unions, wants to focus on drugs such as vaccines, to the detriment of other drugs, certain molecules of which are no longer really profitable.

Newsletter It pays me

The newsletter that improves your purchasing power

Subscribe to the newsletterAll newsletters

Last summer, Sanofi launched investments to the tune of 610 million euros in the Lyon region “to make France its world center of excellence in vaccine research and production.

"In its

Play to Win

strategy,

Sanofi sells or stops 200 of these 300 older molecules that have the least added value: where did the health security so much vaunted by the Management to President Macron go, during his visit to the site? Lyonnais?

», Protests the CFDT.

VIDEO.

Macron visits Sanofi: "Reproduce paracetamol in France"

Especially since this plan comes when the company is doing quite well.

During the first lockdown, the company raised nearly $ 11 billion and redistributed € 4 billion in dividends to its shareholders.

For its part, Sanofi is pleased to have been able to maintain full employment during this period and to have granted a bonus of 1,500 euros to its 15,000 employees mobilized during the epidemic.

The CGT launched a call to walk out on Tuesday to protest against this plan of cuts but also to demand a rise in wages.

“In March and April the management of Sanofi praised the investment of employees particularly around the vaccine and then in December when there were negotiations on wages, it was zero.

After a while this is not possible, ”protests the CGT.

Source: leparis

All business articles on 2021-01-18

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.